Regeneron Pharmaceuticals Stock News

Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Stree

Regeneron Pharmaceuticals Inc.'s stock REGN, +1.44% fell 3% early Thursday, after the company's first-quarter earnings fell short of estimates. The company had net income of $722 million, or $6.27 a s

U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.

Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.

An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.

Regeneron (REGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising

Evaluate the expected performance of Regeneron (REGN) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks is more attractive to value inve

AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to

Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Regeneron Pharmaceuticals said on Monday the U.S. Justice Department's complaint against the company misreporting the average sales price for its macular degeneration drug Eylea is "meritless" and it

The U.S. Department of Justice files a complaint against Regeneron (REGN), alleging fraudulent drug pricing practices related to its lead drug, Eylea.